| [1] |
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J, 2022, 43(40):3997-4126.
|
| [2] |
Semsarian C, Ingles J, Wilde AA. Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives[J]. Eur Heart J, 2015, 36(21):1290-1296.
|
| [3] |
Austin BC, Kowlgi GN, Neves R, et al. Incidence and clinical management of supraventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia[J]. JACC Clin Electrophysiol, 2025, 11(4):792-800.
|
| [4] |
戈海延, 李小梅, 江河, 等. 儿童儿茶酚胺敏感性多形性室性心动过速临床分析[J]. 中华儿科杂志, 2017, 55(12):926-931.
|
| [5] |
Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia[J]. Heart Rhythm, 2011, 8(6):864-871.
|
| [6] |
Sumitomo N, Sakurada H, Taniguchi K, et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia[J]. Circ J, 2007, 71(10):1606-1609.
|
| [7] |
Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry[J]. Circ Arrhythm Electrophysiol, 2015, 8(3):633-642.
|
| [8] |
Peltenburg PJ, Kallas D, Bos JM, et al. An international multicenter cohort study on β-blockers for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia[J]. Circulation, 2022, 145(5):333-344.
|
| [9] |
Mazzanti A, Kukavica D, Trancuccio A, et al. Outcomes of patients with catecholaminergic polymorphic ventricular tachycardia treated with β-blockers[J]. JAMA Cardiol, 2022, 7(5):504-512.
|
| [10] |
Bergeman AT, Lieve K, Kallas D, et al. Flecainide is associated with a lower incidence of arrhythmic events in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia[J]. Circulation, 2023, 148(25):2029-2037.
|
| [11] |
Kannankeril PJ, Moore JP, Cerrone M, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial[J]. JAMA Cardiol, 2017, 2(7):759-766.
|
| [12] |
Padfield GJ, AlAhmari L, Lieve KV, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade[J]. Heart Rhythm, 2016, 13(2):609-613.
|
| [13] |
戈海延, 李小梅, 江河, 等. 平板运动试验对儿童儿茶酚胺敏感性多形性室性心动过速的诊治价值分析[J]. 中国心血管杂志, 2021, 26(1):21-26.
|
| [14] |
毛家亮, 孙建英, 李若谷, 等. 心血管植入型电子器械手术伴心理疾病的现状及诊治[J/OL]. 中华心脏与心律电子杂志, 2022, 10(2): 110-112.
|
| [15] |
Roston TM, Jones K, Hawkins NM, et al. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: a systematic review[J]. Heart Rhythm, 2018, 15(12):1791-1799.
|